Last reviewed · How we verify
Measles and inactivated polio vaccine
Measles and inactivated polio vaccine is a vaccine Biologic drug developed by Bandim Health Project. It is currently FDA-approved for Prevention of measles, Prevention of poliomyelitis.
This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against measles virus and poliovirus by delivering inactivated viral antigens.
This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against measles virus and poliovirus types 1, 2, and 3. Used for Prevention of measles, Prevention of poliomyelitis (types 1, 2, and 3).
At a glance
| Generic name | Measles and inactivated polio vaccine |
|---|---|
| Sponsor | Bandim Health Project |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) measles virus and inactivated poliovirus particles that trigger both humoral and cell-mediated immune responses. Upon administration, the immune system recognizes these antigens as foreign and generates specific antibodies and memory T cells. This immunological memory provides protection against future natural infection with these viruses.
Approved indications
- Prevention of measles
- Prevention of poliomyelitis
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia
- Headache
Key clinical trials
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines (PHASE1)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (PHASE2)
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Measles and inactivated polio vaccine CI brief — competitive landscape report
- Measles and inactivated polio vaccine updates RSS · CI watch RSS
- Bandim Health Project portfolio CI
Frequently asked questions about Measles and inactivated polio vaccine
What is Measles and inactivated polio vaccine?
How does Measles and inactivated polio vaccine work?
What is Measles and inactivated polio vaccine used for?
Who makes Measles and inactivated polio vaccine?
What drug class is Measles and inactivated polio vaccine in?
What development phase is Measles and inactivated polio vaccine in?
What are the side effects of Measles and inactivated polio vaccine?
Related
- Drug class: All vaccine drugs
- Manufacturer: Bandim Health Project — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of measles
- Indication: Drugs for Prevention of poliomyelitis
- Compare: Measles and inactivated polio vaccine vs similar drugs
- Pricing: Measles and inactivated polio vaccine cost, discount & access